Grants per year
Personal profile
Research Interests
Dr. Laumann's clinical interests include the diagnosis and treatment of complex medical dermatologic disorders including collagen vascular, psychocutaneous, and genital diseases. She has a particular interest in fibrosing, pruritic and other disorders related to renal dysfunction, as well as Raynaud's syndrome. She has an ongoing interest in the various aspects of the application of body art and how this may be used to help functioning. Currently, she is involved with other research studies related to psoriasis, atopic dermatitis, nephrogenic systemic fibrosis, systemic sclerosis, morphea, dermatomyositis, and lupus erythematosus.
Certifications and Licenses
| Dermatology |
Training Experience
| 1979 | Residency, University of Chicago Hospitals |
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
MRCP (UK), Royal College of Physicians of the UK
… → 1973
MBChB, University of Birmingham
… → 1968
Research interests keywords
- Dermatology
Fingerprint
Dive into the research topics where Anne E Laumann is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Grants
- 36 Finished
-
Prot #GS-US-436-4092: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib and GS-9876 in Female Subjects with Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)
Laumann, A. E. (PD/PI)
ICON Clinical Research, L.P., Gilead Sciences, Inc
7/27/17 → 7/27/20
Project: Research project
-
Prot #8400-211: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 In Patients with Dermatomyositis
Laumann, A. E. (PD/PI)
Parexel, Idera Pharmaceuticals, Inc.
3/14/16 → 3/14/19
Project: Research project
-
Prot #CC-220-SLE-001: A PILOT, PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, STUDY TO EVALUATE EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND PHARMACOGENETICS OF CC-220 IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Laumann, A. E. (PD/PI)
PPD Development, Celgene Corporation
4/7/15 → 4/7/19
Project: Research project
-
Prot #X052171: A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Patients with Pyoderma Gangrenosum
Laumann, A. E. (PD/PI)
Therapeutics, Inc., XOMA (US) LLC
3/19/15 → 3/19/18
Project: Research project
-
Prot #X052172: A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum
Laumann, A. E. (PD/PI)
Clinipace, Inc., XOMA (US) LLC
3/19/15 → 3/19/18
Project: Research project
-
An Analysis of the Content and Recommendations of 700 American Tattoo Aftercare Instructions
Liszewski, W., Newcomer, J., Laumann, A. E., Leger, M. C. & Farah, R. S., Dec 1 2023, In: Dermatology. 239, 6, p. 988-995 8 p.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
History of Cosmetic and Medical Tattoos
Laumann, A. E., Jun 1 2023, Current Problems in Dermatology (Switzerland). Serup, J., Ercegovac, M., Bennoun, I. & Hvas, D. (eds.). S. Karger AG, p. 1-4 4 p. (Current Problems in Dermatology (Switzerland); vol. 56).Research output: Chapter in Book/Report/Conference proceeding › Chapter
1 Scopus citations -
Effect of Costimulatory Blockade with Abatacept after Ustekinumab Withdrawal in Patients with Moderate to Severe Plaque Psoriasis: The PAUSE Randomized Clinical Trial
Harris, K. M., Smilek, D. E., Byron, M., Lim, N., Barry, W. T., McNamara, J., Garcet, S., Konrad, R. J., Stengelin, M., Bathala, P., Korman, N. J., Feldman, S. R., Boh, E. E., Barber, K., Laumann, A. E., Helfrich, Y. R., Krueger, G. G., Sofen, H., Bissonnette, R. & Krueger, J. G., Nov 2021, In: JAMA dermatology. 157, 11, p. 1306-1315 10 p.Research output: Contribution to journal › Article › peer-review
18 Scopus citations -
Developing classification criteria for skin-predominant dermatomyositis: the Delphi process
The Skin Myositis Delphi Group, Feb 1 2020, In: British Journal of Dermatology. 182, 2, p. 410-417 8 p.Research output: Contribution to journal › Article › peer-review
Open Access28 Scopus citations -
Evaluation of the Effectiveness and Tolerability of Mycophenolate Mofetil and Mycophenolic Acid for the Treatment of Morphea
Arthur, M., Fett, N. M., Latour, E., Jacobe, H., Kunzler, E., Florez-Pollack, S., Houser, J., Sharma, S., Prasad, S., Femia, A., Stern, M. J., Pappas-Taffer, L. K., Gaffney, R., Fernandez, A. P., Knabel, D., Cardones, A. R., Leung, N., Laumann, A., Yu, J. M. & Zhao, J. & 3 others, , May 2020, In: JAMA dermatology. 156, 5, p. 521-528 8 p.Research output: Contribution to journal › Article › peer-review
Open Access27 Scopus citations